Electromed (ELMD) The 38th Annual Roth Conference summary

Company overview and financials

• Focuses on airway clearance in the respiratory care space, with a 35-year history and public since 2010.

• Generates about $70 million in revenue and $12 million in operating income, with no debt.

• Profitable growth, strong cash generation, and unique in the small cap medical device sector.

• Invests in organic growth and returns excess cash to shareholders via share repurchases.

• Completed $10 million in share repurchases last fiscal year, with another $10 million authorized.

Product innovation and differentiation

• SmartVest provides 360-degree airway clearance for chronic, irreversible bronchiectasis.

• Features include a lightweight, Velcro-closure vest, single-hose patented design, and touch screen for ease of use.

• Lifetime warranty after insurance obligations, reducing patient out-of-pocket costs.

• High-touch model with respiratory therapists for setup and ongoing support.

• Differentiation includes best-in-class design, comfort, and patient retention on therapy.

Market opportunity and strategy

• Addressable market includes 925,000 diagnosed bronchiectasis patients, but only 150,000 currently treated with HFCWO technology.

• Estimated $3 billion market opportunity based on average selling price of $10,500 per device.

• Additional 4.1 million undiagnosed patients overlap with COPD, representing further growth potential.

• Plans to expand sales force to 61 reps and target high-diagnosing, low-prescribing pulmonologists.

• Market development efforts and partnerships with distributors to improve payer coverage and access.